Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-12.91	-11.91	-16.52	-5.11	-3.49
Depreciation & Amortization	0.01	0.01	0.03	0.05	0.06
Stock-Based Compensation	0.46	0.13	5.86	0.13	0.13
Other Adjustments	0.27	0.34	3.82	0.32	-0.27
Change in Receivables	-0.05	-	-	-	-0.04
Changes in Accounts Payable	0.19	-0.14	0.61	0.08	-0.04
Changes in Accrued Expenses	-0.08	0.24	0.44	0.31	-0.06
Changes in Other Operating Activities	-0.05	0.51	-2.63	-0.31	0.38
Operating Cash Flow	-12.01	-10.82	-8.4	-4.53	-3.34
Capital Expenditures	-0	-0.01	-0.02	-0.01	-0.04
Sale of Property, Plant & Equipment	-	-	-	0.08	-
Purchases of Investments	-	-0.01	-	-	-0.5
Proceeds from Sale of Investments	-	-	-	0.51	0.02
Investing Cash Flow	-0.01	-0.01	-0.02	0.57	-0.52
Long-Term Debt Repaid	-	-0.7	-0.25	-	-
Net Long-Term Debt Issued (Repaid)	-	-0.7	-0.25	-	-
Issuance of Common Stock	9.62	18.68	5.35	-	0
Net Common Stock Issued (Repurchased)	9.62	18.68	5.35	-	0
Issuance of Preferred Stock	-	-	-	0.52	2.75
Net Preferred Stock Issued (Repurchased)	-	-	-	0.52	2.75
Other Financing Activities	-1.33	-2.34	-	-	-
Financing Cash Flow	8.29	15.64	5.1	0.52	2.75
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.01	-0	-0.06	-0.23	-0.67
Net Cash Flow	-3.73	4.81	-3.31	-3.43	-1.11
Free Cash Flow	-12.02	-10.83	-8.42	-4.54	-3.38
Free Cash Flow Per Share	-5.94	-8.14	-202.19	-609.66	-453.28
Levered Free Cash Flow	-10.1	-12	-18.27	-4.82	-2.92
Unlevered Free Cash Flow	-9.91	-11.03	-14.16	-4.59	-3.59

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q